{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:40:22Z","timestamp":1784990422300,"version":"3.55.0"},"reference-count":81,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2023.2627","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T10:58:52Z","timestamp":1677063532000},"source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy in malignant peritoneal mesothelioma (Review)"],"prefix":"10.3892","volume":"18","author":[{"given":"Sabah","family":"Alaklabi","sequence":"first","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Skitzki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology\/Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"key20230317120441_b1-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"32","key":"key20230317120441_b2-MCO-18-4-02627","article-title":"Peritoneal mesothelioma: A review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"key":"key20230317120441_b3-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","article-title":"US mesothelioma patterns 1973-2002: Indicators of change and insights into background rates","volume":"17","author":"Teta","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"key20230317120441_b4-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::aid-cncr2820461233>3.0.co;2-l","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff","year":"1980","journal-title":"Cancer"},{"key":"key20230317120441_b5-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"key20230317120441_b6-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key20230317120441_b7-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: A surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"942","key":"key20230317120441_b8-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040942","article-title":"Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): A population-based study from SEER Database","volume":"14","author":"Ullah","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20230317120441_b9-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"key":"key20230317120441_b10-MCO-18-4-02627","first-page":"313","article-title":"Clinical presentation and natural history of benign and malignant mesothelioma","volume":"8","author":"Antman","year":"1981","journal-title":"Semin Oncol"},{"key":"key20230317120441_b11-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the management of malignant peritoneal mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"key20230317120441_b12-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/02656736.2017.1320591","article-title":"Current management strategies for peritoneal mesothelioma","volume":"33","author":"Turaga","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"key20230317120441_b13-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jss.2022.04.005","article-title":"Expression of PD-L1 in patients with malignant peritoneal mesothelioma: A pilot study","volume":"277","author":"Gazivoda","year":"2022","journal-title":"J Surg Res"},{"key":"key20230317120441_b14-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1245\/s10434-015-4965-6","article-title":"Malignant Peritoneal Mesothelioma: Characterization of the inflammatory response in the tumor microenvironment","volume":"23","author":"Judge","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"5804230","key":"key20230317120441_b15-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5804230","article-title":"Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of adaptive immunological signature in the more aggressive histological types","volume":"2018","author":"Tazzari","year":"2018","journal-title":"J Immunol Res"},{"key":"key20230317120441_b16-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"key20230317120441_b17-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"key20230317120441_b18-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"key20230317120441_b19-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1119-6","article-title":"Genetic instability and increased mutational load: Which diagnostic tool best direct patients with cancer to immunotherapy?","volume":"15","author":"Palmieri","year":"2017","journal-title":"J Transl Med"},{"key":"key20230317120441_b20-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/cgt.2016.63","article-title":"Gene-expression profiling to predict responsiveness to immunotherapy","volume":"24","author":"Jamieson","year":"2017","journal-title":"Cancer Gene Ther"},{"issue":"34","key":"key20230317120441_b21-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"key20230317120441_b22-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: A predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20230317120441_b23-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"key20230317120441_b24-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20230317120441_b25-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20230317120441_b26-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/carcin\/bgm228","article-title":"Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics","volume":"29","author":"Imai","year":"2008","journal-title":"Carcinogenesis"},{"key":"key20230317120441_b27-MCO-18-4-02627","first-page":"1635","article-title":"The tumor spectrum in HNPCC","volume":"14 (4B)","author":"Watson","year":"1994","journal-title":"Anticancer Res"},{"issue":"PO.17.00073","key":"key20230317120441_b28-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"key20230317120441_b29-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"key20230317120441_b30-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 Blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"e2025109","key":"key20230317120441_b31-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"key20230317120441_b32-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"key20230317120441_b33-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"S339","key":"key20230317120441_b34-MCO-18-4-02627","article-title":"OA08.05 quantifying tumour infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM)-defining the hot, the warm and the cold tumours","volume":"13","author":"Thapa","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key20230317120441_b35-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol"},{"key":"key20230317120441_b36-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/annonc\/mdv560","article-title":"Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer","volume":"27","author":"Donnem","year":"2016","journal-title":"Ann Oncol"},{"key":"key20230317120441_b37-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"key20230317120441_b38-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"200ra116","key":"key20230317120441_b39-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20230317120441_b40-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"key20230317120441_b41-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"key20230317120441_b42-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humimm.2005.11.005","article-title":"Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma","volume":"67","author":"Meloni","year":"2006","journal-title":"Hum Immunol"},{"issue":"187","key":"key20230317120441_b43-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01449-2","article-title":"Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC\/mesothelin expression","volume":"21","author":"Kojima","year":"2020","journal-title":"Respir Res"},{"key":"key20230317120441_b44-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"key20230317120441_b45-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"key20230317120441_b46-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1084\/jem.20181827","article-title":"Context-dependent EMT programs in cancer metastasis","volume":"216","author":"Aiello","year":"2019","journal-title":"J Exp Med"},{"key":"key20230317120441_b47-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20230317120441_b48-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of EMT in tumor immune escape","volume":"11","author":"Terry","year":"2017","journal-title":"Mol Oncol"},{"key":"key20230317120441_b49-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20230317120441_b50-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1172\/JCI124037","article-title":"Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer","volume":"130","author":"Salazar","year":"2020","journal-title":"J Clin Invest"},{"issue":"1333","key":"key20230317120441_b51-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"issue":"1007","key":"key20230317120441_b52-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04973-x","article-title":"A panel of emerging EMT genes identified in malignant mesothelioma","volume":"12","author":"Wu","year":"2022","journal-title":"Sci Rep"},{"key":"key20230317120441_b53-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"key20230317120441_b54-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20230317120441_b55-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"key20230317120441_b56-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.wneu.2017.10.064","article-title":"Malignant peripheral nerve sheath tumor in a Patient with BAP1 tumor predisposition syndrome","volume":"109","author":"Kaszuba","year":"2018","journal-title":"World Neurosurg"},{"issue":"8","key":"key20230317120441_b57-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"key20230317120441_b58-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20230317120441_b59-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"key20230317120441_b60-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"key":"key20230317120441_b61-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"key20230317120441_b62-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20230317120441_b63-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"key20230317120441_b64-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"key20230317120441_b65-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"key20230317120441_b66-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20230317120441_b67-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"key20230317120441_b68-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"S8565","key":"key20230317120441_b69-MCO-18-4-02627","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36 (Suppl 15)","author":"Desai","year":"2018","journal-title":"J Clin Oncol"},{"issue":"e21094","key":"key20230317120441_b70-MCO-18-4-02627","article-title":"Real-world outcomes of pembrolizumab in peritoneal mesothelioma","volume":"38 (Suppl 15)","author":"Marmarelis","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20230317120441_b71-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"key20230317120441_b72-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Calabr\u00f2","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20230317120441_b73-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"e2119934","key":"key20230317120441_b74-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key20230317120441_b75-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"key20230317120441_b76-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/CJI.0000000000000399","article-title":"Treatment of platinum nonresponsive metastatic malignant peritoneal mesothelioma with combination chemoimmunotherapy","volume":"45","author":"Foote","year":"2022","journal-title":"J Immunother"},{"key":"key20230317120441_b77-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"key20230317120441_b78-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1245\/s10434-019-08138-5","article-title":"Predictors and outcomes of surgery in peritoneal mesothelioma: An analysis of 2000 patients from the National cancer database","volume":"27","author":"Bijelic","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"key20230317120441_b79-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","article-title":"Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy","volume":"139","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"issue":"e026779","key":"key20230317120441_b80-MCO-18-4-02627","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026779","article-title":"Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC trial","volume":"9","author":"de Boer","year":"2019","journal-title":"BMJ Open"},{"key":"key20230317120441_b81-MCO-18-4-02627","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T10:04:55Z","timestamp":1679047495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2023.2627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,22]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2023.2627","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"31"}}